This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Nov 2011

European Patent Office Grants Patent for Sativex

The European Patent Office has granted a patent for endocannabinoid modulator Sativex with an exclusivity period until August 2023.

UK's GW Pharmaceuticals has been granted a patent by the European Patent Office, which protects the composition of its Sativex formulation. This patent has already been granted in the US.


Sativex is an endocannabinoid modulator made of two actives – THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol).


The patent, entitled ‘Cannabinoid Liquid Formulations for Mucosal Administration’, provides an exclusivity period until August 2023.


In addition to this patent, Sativex is protected by a number of other patents related to different aspects of the product.


"The grant of this patent is part of a matrix of in

Related News